Alnylam Pharmaceuticals price to free cash flow ALNY
Market value divided by free cash flow over the last twelve months, since 2024.
- Today, Nov 3, 2026
- 26.7×
- 3-year median
- 110×
- Against its 3-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 26.6× to 473×
- Peer median
- 25.1×
Alnylam Pharmaceuticals' price to free cash flow is 26.7× as of Nov 3, 2026.
That is below its 3-year median of 110×, lower than on 99% of days in the last 3 years.
Over that time it ranged from 26.6× in Nov 2026 to 473× in Feb 2024.
The median for 10 biotech stocks of a similar size is 25.1×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 26.6× | 26.6× | 239× |
| 2025 | 239× | 237× | 273× |
| 2024 | 115× | 99.4× | 473× |
Against its peers
Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ALNYAlnylam Pharmaceuticals | 26.7× |
| INCYIncyte | 12.7× |
| UTHRUnited Therapeutics | 23.7× |
| EXELExelixis | 14.8× |
| NBIXNeurocrine Biosciences | 17.0× |
| HALOHalozyme Therapeutics | 18.2× |
| TECHBIO-TECHNE | 43.3× |
| ONCBeOne Medicines | 30.2× |
| RGENRepligen | 87.2× |
| KRYSKrystal Biotech | 34.0× |
| REGNRegeneron Pharmaceuticals | 26.6× |
| Peer median | 25.1× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Alnylam Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.